The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer

Li,Jin; Zhang,Jie Ting; Jiang,Xiaohua; Shi,Xiaoshun; Shen,Jianfei; Feng,Fenglan; Chen,Jingyi; Liu,Guihong; He,Ping; Jiang,Juhong; Tsang,Lai Ling; Wang,Yan; Rosell,Rafael; Jiang,Long; He,Jianxing; Chan,Hsiao Chang

doi:10.3892/ijo.2015.2921

The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer

Authors:
- Jin Li
- Jie Ting Zhang
- Xiaohua Jiang
- Xiaoshun Shi
- Jianfei Shen
- Fenglan Feng
- Jingyi Chen
- Guihong Liu
- Ping He
- Juhong Jiang
- Lai Ling Tsang
- Yan Wang
- Rafael Rosell
- Long Jiang
- Jianxing He
- Hsiao Chang Chan
View Affiliations

Affiliations: State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, Guangzhou, Guangdong, P.R. China, Epithelial Cell Biology Research Center, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, P.R. China, Catalan Institute of Oncology, Badalona, Catalonia, Spain
Published online on: March 6, 2015 https://doi.org/10.3892/ijo.2015.2921
Pages: 2107-2115

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increased risk of non-small cell lung cancer (NSCLC) in cystic fibrosis (CF) patients and carriers of CF transmembrane conductance regulator (CFTR) mutations has been proposed. However, the role of CFTR in lung cancer remains controversial. In the present study, CFTR expression was assessed in 165 NSCLC tumors and 22 normal lung samples with validation in an independent series of 131 samples. The effect of gain and loss of CFTR on the malignant behavior of NSCLC was examined. The effect of CFTR manipulation on tumor metastasis was examined in a mouse model. Expression of CFTR was downregulated in NSCLC (p=0.041). Low CFTR expression was correlated with advanced stage (p<0.001) and lymph node metastasis (p=0.009). Low CFTR expression was significantly associated with poor prognosis (overall survival: 45 vs. 36 months, p<0.0001; progression-free survival: 41 vs. 30 months, p=0.007). Knockdown of CFTR in NSCLC cells enhanced malignant behavior (epithelial-mesenchymal transition, invasion and migration); in contrast, overexpression of CFTR suppressed cancer progression in vitro and in vivo. The tumor-suppressing effect of CFTR was associated with inhibition of multiple uPA/uPAR-mediated malignant traits in culture. These results show that CFTR plays a role in inhibition of NSCLC metastasis and suggest that CFTR may serve as a novel indicator for predicting adverse prognosis and metastasis in NSCLC patients.

View Figures

View References

1	Chang S, Dai M, Ren JS, Chen YH and Guo LW: Estimates and prediction on incidence, mortality and prevalence of lung cancer in China in 2008. Zhonghua Liu Xing Bing Xue Za Zhi. 33:391–394. 2010.(In Chinese).
2	Chien CR and Chen TH: A Bayesian model for age, period, and cohort effects on mortality trends for lung cancer, in association with gender-specific incidence and case-fatality rates. J Thorac Oncol. 4:167–171. 2009. View Article : Google Scholar : PubMed/NCBI
3	Subramanian J, Madadi AR, Dandona M, Williams K, Morgensztern D and Govindan R: Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.govurisimpleClinicalTrials.gov website. J Thorac Oncol. 5:1116–1119. 2010. View Article : Google Scholar : PubMed/NCBI
4	Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science. 256:774–779. 1992. View Article : Google Scholar : PubMed/NCBI
5	Riordan JR, Rommens JM, Kerem B, et al: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 245:1066–1073. 1989. View Article : Google Scholar : PubMed/NCBI
6	McWilliams RR, Rabe KG, Olswold C, De Andrade M and Petersen GM: Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer. 104:388–394. 2005. View Article : Google Scholar : PubMed/NCBI
7	McWilliams RR, Petersen GM, Rabe KG, et al: Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer. 116:203–209. 2010.
8	Neglia JP, FitzSimmons SC, Maisonneuve P, et al: The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 332:494–499. 1995. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Sun Z, Wu Y, et al: Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. Lung Cancer. 70:14–21. 2010. View Article : Google Scholar : PubMed/NCBI
10	Maisonneuve P, Marshall BC, Knapp EA and Lowenfels AB: Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 105:122–129. 2013. View Article : Google Scholar
11	Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP and Vadgama JV: Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther. 9:33–45. 2010. View Article : Google Scholar : PubMed/NCBI
12	Son JW, Kim YJ, Cho HM, et al: Promoter hypermethylation of the CFTR gene and clinical/pathological features associated with non-small cell lung cancer. Respirology. 16:1203–1209. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ding S, Gong BD, Yu J, et al: Methylation profile of the promoter CpG islands of 14 ‘drug-resistance’ genes in hepatocellular carcinoma. World J Gastroenterol. 10:3433–3440. 2004.PubMed/NCBI
14	Abraham EH, Vos P, Kahn J, et al: Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth. Nat Med. 2:593–596. 1996. View Article : Google Scholar : PubMed/NCBI
15	O’Connell MP, Fiori JL, Baugher KM, et al: Wnt5A activates the calpain-mediated cleavage of filamin A. J Invest Dermatol. 129:1782–1789. 2009. View Article : Google Scholar
16	Govindan R, Ding L, Griffith M, et al: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
17	Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar
18	Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li J, Ye L, Mansel RE and Jiang WG: Potential prognostic value of repulsive guidance molecules in breast cancer. Anticancer Res. 31:1703–1711. 2011.PubMed/NCBI
20	Smith SM, Vaughan JM, Donaldson CJ, et al: Cocaine- and amphetamine-regulated transcript is localized in pituitary lactotropes and is regulated during lactation. Endocrinology. 147:1213–1223. 2006. View Article : Google Scholar
21	Vij N, Mazur S and Zeitlin PL: CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One. 4:e46642009. View Article : Google Scholar : PubMed/NCBI
22	DiMango E, Ratner AJ, Bryan R, Tabibi S and Prince A: Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest. 101:2598–2605. 1998. View Article : Google Scholar : PubMed/NCBI
23	Boncoeur E, Roque T, Bonvin E, et al: Cystic fibrosis trans-membrane conductance regulator controls lung proteasomal degradation and nuclear factor-kappaB activity in conditions of oxidative stress. Am J Pathol. 172:1184–1194. 2008. View Article : Google Scholar : PubMed/NCBI
24	Smith HW and Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010. View Article : Google Scholar
25	Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
26	Kohno T, Ichikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377. 2012. View Article : Google Scholar : PubMed/NCBI
27	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
28	Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012. View Article : Google Scholar : PubMed/NCBI
29	Strongin AY: Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta. 1803:133–141. 2010. View Article : Google Scholar :
30	Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 1:a0016512009. View Article : Google Scholar
31	Sen R and Smale ST: Selectivity of the NF-{kappa}B response. Cold Spring Harb Perspect Biol. 2:a0002572010. View Article : Google Scholar : PubMed/NCBI
32	Pruliere-Escabasse V, Fanen P, Dazy AC, et al: TGF-beta 1 downregulates CFTR expression and function in nasal polyps of non-CF patients. Am J Physiol Lung Cell Mol Physiol. 288:L77–L83. 2005. View Article : Google Scholar
33	Howe KL, Wang A, Hunter MM, Stanton BA and McKay DM: TGFbeta down-regulation of the CFTR: a means to limit epithelial chloride secretion. Exp Cell Res. 298:473–484. 2004. View Article : Google Scholar : PubMed/NCBI
34	Xie C, Jiang XH, Zhang JT, et al: CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene. 32:2282–2291. 2013. View Article : Google Scholar
35	Sun TT, Wang Y, Cheng H, et al: Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochim Biophys Acta. 1843:618–628. 2014. View Article : Google Scholar : PubMed/NCBI
36	Zhang JT, Jiang XH, Xie C, et al: Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta. 1833:2961–2969. 2013. View Article : Google Scholar : PubMed/NCBI
37	Ramsey BW, Davies J, McElvaney NG, et al: A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 365:1663–1672. 2011. View Article : Google Scholar : PubMed/NCBI
38	Yang S, Yu BO, Sui Y, et al: CFTR chloride channel is a molecular target of the natural cancer preventive agent resveratrol. Pharmazie. 68:772–776. 2013.PubMed/NCBI